Seroprevalence of Zika in Brazil stratified by age and geographic distribution
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
CAMBRIDGE UNIV PRESS
Autores
BOTOSSO, Viviane Fongaro
PRECIOSO, Alexander Roberto
WILDER-SMITH, Annelies
OLIVEIRA, Danielle Bruna Leal de
OLIVEIRA, Fabyano Bruno Leal de
OLIVEIRA, Cairo Monteiro De
SOARES, Camila Pereira
OLIVEIRA, Lucyana Trindade Leal
SANTO, Ralyria Mello Vieira dos
UTESCHER, Carla Lilian de Agostini
Citação
EPIDEMIOLOGY AND INFECTION, v.151, article ID e197, 7p, 2023
Resumo
Congenital Zika is a devastating consequence of maternal Zika virus infections. Estimates of age-dependent seroprevalence profiles are central to our understanding of the force of Zika virus infections. We set out to calculate the age-dependent seroprevalence of Zika virus infections in Brazil. We analyzed serum samples stratified by age and geographic location, collected from 2016 to 2019, from about 16,000 volunteers enrolled in a Phase 3 dengue vaccine trial led by the Institute Butantan in Brazil. Our results show that Zika seroprevalence has a remarkable age-dependent and geographical distribution, with an average age of the first infection varying from region to region, ranging from 4.97 (3.03-5.41) to 7.24 (6.98-7.90) years. The calculated basic reproduction number, $ {R}_0 $, varied from region to region, ranging from 1.18 (1.04-1.41) to 2.33 (1.54-3.85). Such data are paramount to determine the optimal age to vaccinate against Zika, if and when such a vaccine becomes available.
Palavras-chave
arboviruses, emerging infections, epidemiology, mathematical modelling, Zika virus
Referências
- Akrami KM, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa165
- Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
- Angelo KM, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa061
- Aubry F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21199-z
- Aubry F, 2020, SCIENCE, V370, P991, DOI 10.1126/science.abd3663
- Badgett MR, 2002, J VIROL, V76, P10524, DOI 10.1128/JVI.76.20.10524-10529.2002
- Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03497-1
- Castro KR, 2023, TALANTA, V256, DOI 10.1016/j.talanta.2023.124277
- Clemente NS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69235-0
- de Caires LC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02790-9
- de Souza WV, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5039-z
- Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
- Heffernan JM, 2005, J R SOC INTERFACE, V2, P281, DOI 10.1098/rsif.2005.0042
- Kam YW, 2017, J INFECT DIS, V216, P172, DOI 10.1093/infdis/jix261
- Kanno AI, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-019-0926-y
- Lambrechts L, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab041
- Maier SB, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-019-00690-1
- Massad E, 2017, EPIDEMIOL INFECT, V145, P2303, DOI 10.1017/S0950268817001200
- MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
- MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
- Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
- O'Reilly KM, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1158-8
- Oliveira DBL, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110615
- Oliveira DBL, 2016, NEW ENGL J MED, V375, P1202, DOI 10.1056/NEJMc1607583
- Pereira SS, 2021, INT J INFECT DIS, V112, P202, DOI 10.1016/j.ijid.2021.09.009
- Precioso AR, 2015, VACCINE, V33, P7121, DOI 10.1016/j.vaccine.2015.09.105
- Vannice KS, 2019, VACCINE, V37, P863, DOI 10.1016/j.vaccine.2018.12.040
- Villela DAM, 2017, EPIDEMIOL INFECT, V145, P1649, DOI 10.1017/S0950268817000358
- Watts Alexander G, 2018, J Travel Med, V25, DOI 10.1093/jtm/tay132
- Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa227
- Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x
- Wiwanitkit V, 2016, J Nepal Health Res Counc, V14, P71
- Zanetta DMT, 2003, VACCINE, V21, P3795, DOI 10.1016/S0264-410X(03)00315-3